CURX
Curanex Pharmaceuticals Inc Common Stock
NASDAQ: CURX · HEALTHCARE · BIOTECHNOLOGY
$0.42
+0.72% today
Updated 2026-04-30
Market cap
$12.38M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$0 – $9
Volume
5.3M
Curanex Pharmaceuticals Inc Common Stock (CURX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $26000.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -100.0% | — | — |
| Cost of revenue | $21571.00 | $0.00 | — | — |
| Gross profit | $4429.00 | $0.00 | — | — |
| Gross margin | 17.0% | — | — | — |
| R&D | — | — | $0.00 | $2.99M |
| SG&A | $24662.00 | $19298.00 | $290386.00 | $1.25M |
| Operating income | $-20233.00 | $-19298.00 | $-365062.00 | $-4.24M |
| Operating margin | -77.8% | — | — | — |
| EBITDA | $925.00 | $-17483.00 | $-290386.00 | $-4.24M |
| EBITDA margin | 3.6% | — | — | — |
| EBIT | $-20233.00 | $-19298.00 | — | — |
| Interest expense | — | — | $0.00 | $8537.00 |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-20233.00 | $-19198.00 | $-361506.00 | $-4.23M |
| Net income growth (YoY) | — | +5.1% | -1783.0% | -1068.8% |
| Profit margin | -77.8% | — | — | — |